This reference uses VA rating codes. For a code from a medical record, check ICD-10-CM and the service date. A clinical code alone does not establish a VA rating or a matching VA diagnostic code.
Erythroderma
Skin · 38 CFR § 4.118
Diagnostic Code 7817 is the VASRD entry for Erythroderma. VA applies the controlling criteria, shared formulas, and special instructions shown in 38 CFR Part 4. VMC presents this material for education and reference; it does not determine a Veteran's diagnosis, service connection, or evaluation.
Print the source-verified reference on this page, or choose Save as PDF in your browser’s print dialog.
Source-verified VASRD criteria
How VA rates this diagnostic code
These percentages summarize the regulatory criteria already mapped to this diagnostic code. They do not predict a Veteran's individual evaluation or establish service connection.
Generalized involvement of the skin with systemic manifestations (such as fever, weight loss, or hypoproteinemia) AND one of the following
No current treatment due to a documented history of treatment failure with 2 or more treatment regimens
No current treatment due to a documented history of treatment failure with 1 treatment regimen
Any extent of involvement of the skin, and any of the following therapies required for a total duration of 6 weeks or more, but not constantly, over the past 12-month period: systemic therapy such as therapeutic doses of corticosteroids, other immunosuppressive drugs, retinoids, PUVA, UVB treatments, biologics, or electron beam therapy
Any extent of involvement of the skin, and any of the following therapies required for a total duration of less than 6 weeks over the past 12-month period: systemic therapy such as therapeutic doses of corticosteroids, other immunosuppressive drugs, retinoids, PUVA, UVB treatments, biologics, or electron beam therapy
Any extent of involvement of the skin, and no more than topical therapy required over the past 12-month period
Special rating instructions
- Constant or near-constant systemic therapy such as therapeutic doses of corticosteroids, other immunosuppressive drugs, retinoids, PUVA (psoralen with long-wave ultraviolet-A light), UVB (ultraviolet-B light) treatments, biologics, or electron beam therapy required over the past 12 month period; or
- Generalized involvement of the skin without systemic manifestations and one of the following
- Constant or near-constant systemic therapy such as therapeutic doses of corticosteroids, other immunosuppressive drugs, retinoids, PUVA, UVB treatments, biologics, or electron beam therapy required over the past 12-month period; or
Regulatory notes
- Note: Treatment failure is defined as either disease progression, or less than a 25 percent reduction in the extent and severity of disease after four weeks of prescribed therapy, as documented by medical records
Body system and anatomy metadata
Body system: Skin
Anatomy / region tags: multi region
These tags support discovery and body-map compatibility. They do not establish Veteran-specific laterality or entitlement.
Official VA DBQ references
DBQ catalog: va-dbq-2026.09.16 · Retrieved 2026-09-16. Official VA inventory ↗
- Scars ↗ Related resourceCatalog category: Dermatological
Related by body system only. No reviewed condition-specific form match or requirement has been established.
- Skin Diseases ↗ Related resourceCatalog category: Dermatological
Related by body system only. No reviewed condition-specific form match or requirement has been established.
VA maintains some examination forms that are not available for public use. VMC does not infer a one-code-to-one-DBQ relationship.
Evidence information
When reviewing the criteria, useful evidence categories can include diagnosis and treatment records, objective testing identified by the schedule, documented frequency/duration/severity when the criteria use those concepts, and functional effects described in medical or lay evidence. The relevant evidence depends on the actual claim and medical facts.
VMC does not diagnose conditions, guarantee a percentage, or advise anyone to exaggerate symptoms.
Legal basis and source identification
38 CFR § 4.118 · Source current through 2026-08-06 · Verified 2026-08-10
Registry content release: vasrd-registry-2026.08.1